FDA Denies Bid to Exempt Radiology AI From 510(k) Review

FDA has formally closed out its rejection of a petition that would have let some radiology AI devices reach the market without a new 510(k) clearance. A final order implementing the agency’s April denial took effect Thursday, 17 September 2026, keeping premarket notification mandatory for computer-aided detection, diagnosis and triage software even when a developer has already cleared an earlier product in the same device category.

What Harrison.ai asked FDA to change

The petition, submitted in October 2025 by Rubrum Advising on Harrison.ai’s behalf, targeted a specific and consequential category: radiology computer-aided detection and diagnosis software for lesions suspicious of cancer, medical image analyzers, and computer-aided triage and notification tools — six product codes across four generic device categories. The proposal was conditional, not a blanket exemption: once a manufacturer obtained at least one 510(k) clearance within a given regulation, the petition argued, later devices under that same regulation should not need a fresh 510(k), provided the manufacturer met post-market monitoring, transparency and training obligations.

The logic tracks a real operational pain point for AI/software as a medical device (SaMD) developers: model architectures and training data shift between product generations, and the current 510(k) process was not built around that pace of iteration. Harrison.ai’s pitch was to trade a case-by-case premarket review for a monitored, self-assessed risk framework after the first clearance in a category.

FDA's answer: one clearance doesn't vouch for the next one

FDA’s April 2026 denial letter concluded that the petition did not demonstrate premarket notification was unnecessary to assure the devices’ safety and effectiveness. Coverage of the agency’s reasoning centers on two points: that clearance of one AI device from a developer is not evidence that a later, architecturally different product from the same company will perform as safely, particularly once the underlying model or training data changes; and that leaning on manufacturers’ own post-market monitoring as the primary safety check goes further than FDA is currently willing to go, given how early post-market AI monitoring practice still is across the industry.

• 1 April 2026 — FDA sends its substantive denial letter on the petition.
• 29 December 2025 — FDA opens the petition for public comment via Federal Register notice.
• 47 comments received on the docket, described by trade coverage as overwhelmingly negative toward the proposed exemption.
• 17 September 2026 — the Federal Register final order implementing the denial (FR document 2026-19074, 91 FR 58817) takes effect.

What doesn't change, and what to watch

Nothing about the practical requirement shifts on 17 September: these radiology AI devices already needed 510(k) clearance, and they still do. What the final order does is close the rulemaking record — it is FDA’s formal, published answer to a specific, well-argued industry proposal for a lighter-touch AI change-control pathway. For regulatory teams at SaMD and radiology-AI companies, the useful signal is less the outcome than the reasoning: FDA is not yet willing to treat a first clearance as a template that later, materially different models can inherit, and it does not yet see post-market AI monitoring as mature enough to carry that weight on its own. Any future proposal along these lines will need to answer those two objections directly rather than restate the efficiency case.

Frequently asked questions

What did Harrison.ai ask for?

In October 2025, Rubrum Advising, acting for the Australian AI company Harrison.ai, petitioned FDA (Docket FDA-2025-P-5560) for a partial exemption from 510(k) premarket notification covering radiology computer-aided detection and diagnosis (CADe/CADx) and computer-aided triage and notification (CADt) software — product codes POK, MYN, QAS, QFM, QBS and QDQ. Under the proposal, once a manufacturer held one 510(k) clearance within a given regulation, later devices in that same regulation would not need a new 510(k), provided the manufacturer met post-market monitoring, transparency and training conditions.

Why did FDA deny it?

FDA said the petition did not demonstrate that premarket notification is unnecessary to assure the safety and effectiveness of the devices in question. The agency's reasoning centered on the fact that one cleared device does not show that a developer's later products — especially ones built on shifted model architectures or new training data — will perform as safely, and it was reluctant to rely primarily on post-market AI monitoring, which it views as still immature.

When did this happen, and what changed on 17 September?

FDA sent its substantive denial letter on 1 April 2026. The Federal Register final order that formally implements that denial — FR document 2026-19074 (91 FR 58817) — took effect Thursday, 17 September 2026. The practical requirement, that these radiology AI devices go through 510(k) review, has not changed; the order closes out the rulemaking record on the petition.

How much public comment did the petition draw?

FDA opened the petition for public comment (Federal Register, 29 December 2025) and received 47 comments. Coverage of the docket describes the response as overwhelmingly negative, with industry and safety advocates warning the proposed exemption was too broad and that post-market AI monitoring was not yet mature enough to serve as a substitute safeguard.